All In Biotech

Drug Trial Radar · NCT07617597

Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Japanese Adults With Severe Alopecia Areata

A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adult Patients With Severe Alopecia Areata With an Open-Label Extension Period

Last checked: Nov 20, 2026Latest source record: Oct 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

78

Planned (sponsor's estimate)

Start

Jun 19, 2026

Primary completion

Feb 2028

Study completion Sep 2028

Sponsor

Lead sponsor
Sun Pharma Japan LimitedIndustry
Sponsor type
Industry
First posted
Jun 1, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study evaluates the efficacy and safety of deuruxolitinib in Japanese Adults between 18 and 65 years of age who have 50% or greater scalp hair loss.

Conditions

  • Alopecia Areata

Interventions

  • DeuruxolitinibDrug

    Deuruxolitinib will be dosed orally as tablets at a dose of 8 mg

  • PlaceboDrug

    Deuruxolitinib matching placebo will be dosed orally as tablets for up to 24 weeks and then deuruxolitinib will be dosed for up to 52 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of subjects achieving an absolute SALT score of 20 or lessTime frame: Week 24

Locations

18 sites in 1 country. Site status is shown where the registry gives one.

  • Study Site 102

    Asahikawa, Japan · Recruiting

  • Study Site 117

    Bunkyō City, Japan · Recruiting

  • Study Site 119

    Ebina, Japan · Recruiting

  • Study Site 101

    Hamamatsu, Japan · Recruiting

  • Study Site 116

    Ishikawa, Japan · Recruiting

  • Study Site 112

    Kitakyushu, Japan · Recruiting

  • Study Site 118

    Kōtoku, Japan · Recruiting

  • Study Site 110

    Kurashiki, Japan · Recruiting

  • Study Site 113

    Kurume, Japan · Recruiting

  • Study Site 107

    Kyoto, Japan · Recruiting

  • Study Site 106

    Mitaka-shi, Japan · Recruiting

  • Study Site 114

    Miyagi-gun, Japan · Withdrawn

  • Study Site 104

    Niigata, Japan · Recruiting

  • Study Site 109

    Osaka, Japan · Recruiting

  • Study Site 108

    Osaka, Japan · Recruiting

  • Study Site 103

    Sapporo, Japan · Recruiting

  • Study Site 105

    Shinjuku-Ku, Japan · Recruiting

  • Study Site 111

    Ube, Japan · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.